Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 0 | 0 | 570 | 236 | 643 |
| Cost of Goods | 343 | -80 | -222 | 247 | 708 |
| Gross Profit | -343 | 80 | 792 | -11 | -65 |
| Operating Expenses | 9,575 | 32,767 | 8,229 | 3,986 | 7,793 |
| Operating Income | -9,575 | -32,767 | -7,659 | -3,750 | -7,150 |
| Interest Expense | 0 | 0 | 1,864 | 1,553 | 0 |
| Other Income | 108,045 | -88,516 | 1,346 | 83 | -1,036 |
| Pre-tax Income | 98,470 | -121,283 | -8,177 | -5,220 | -8,186 |
| Income Tax | 7 | 7 | -9 | 8 | 7 |
| Net Income Continuous | 98,463 | -121,290 | -8,168 | -5,228 | -8,193 |
| Net Income | $98,463 | $-121,290 | $-8,168 | $-5,228 | $-8,193 |
| EPS Basic Total Ops | 4.21 | -141.00 | 256.92 | -26.19 | -140.73 |
| EPS Basic Continuous Ops | 95.23 | -141.14 | 258.11 | -26.62 | -141.26 |
| EPS Diluted Total Ops | -14.07 | -141.00 | 256.92 | -26.19 | -140.73 |
| EPS Diluted Continuous Ops | 12.87 | -141.14 | 258.11 | -26.62 | -141.26 |
| EPS Diluted Before Non-Recurring Items | -14.07 | -5.98 | N/A | -26.19 | -140.48 |
| EBITDA(a) | $-9,542 | $-32,733 | $-3,709 | $-2,580 | $-6,760 |